Thomas Nystrom
Overview
Explore the profile of Thomas Nystrom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
254
Citations
7731
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen L, Gao Y, Hao X, Yang X, Lindstrom M, Jiang S, et al.
Theranostics
. 2025 Feb;
15(5):1987-2005.
PMID: 39897563
Stress granules (SGs) are membraneless organelles that are formed in response to various stresses. Multiple cellular processes have been reported to be involved in SG formation. However, the signaling cascades...
2.
Fischbach A, Widlund P, Hao X, Nystrom T
J Biol Chem
. 2025 Jan;
301(2):108172.
PMID: 39798875
The mechanistic target of rapamycin (mTOR) signaling pathway appears central to the aging process as genetic or pharmacological inhibition of mTOR extends lifespan in most eukaryotes tested. While the regulation...
3.
Seyed Ahmadi S, Ludvigsson J, Imberg H, Nystrom T, Lind M
JAMA Ophthalmol
. 2024 Dec;
143(2):184-186.
PMID: 39666352
No abstract available.
4.
Chawla S, Molin M, Nystrom T
Neural Regen Res
. 2024 Dec;
20(1):199-200.
PMID: 39657089
No abstract available.
5.
Santos-Pardo I, Andersson Franko M, Nystrom T
J Am Coll Cardiol
. 2024 Nov;
84(22):e321.
PMID: 39567051
No abstract available.
6.
Langslet G, Nystrom T, Vistisen D, Carstensen B, Grip E, Casajust P, et al.
J Diabetes Res
. 2024 Oct;
2024:6142211.
PMID: 39430801
: To evaluate the effectiveness of empagliflozin in reducing all-cause mortality (ACM), hospitalization for heart failure (HHF), myocardial infarction (MI), stroke, cardiovascular mortality (CVM), and end-stage renal disease (ESRD) in...
7.
Nystrom T
Diabetes Obes Metab
. 2024 Jun;
26 Suppl 5:35-57.
PMID: 38859661
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, originally designed to manage blood sugar levels in individuals with type 2 diabetes (T2D), have emerged as a crucial class of drugs for managing cardio-renal...
8.
Glynn L, Lind M, Andersson T, Eliasson B, Hofmann R, Nystrom T
J Am Heart Assoc
. 2024 May;
13(10):e034741.
PMID: 38761078
Background: The aim of this study was to investigate temporal trends in survival and subsequent cardiovascular events in a nationwide myocardial infarction population with and without diabetes. Methods And Results:...
9.
Santos-Pardo I, Andersson Franko M, Lagerqvist B, Ritsinger V, Eliasson B, Witt N, et al.
J Am Coll Cardiol
. 2024 May;
84(3):260-272.
PMID: 38752901
Background: The impact of glycemic control in the risk of stent failure in subjects with type 2 diabetes (T2D) is currently unknown. Objectives: This study sought to study whether poor...
10.
Sterner Isaksson S, Imberg H, Hirsch I, Schwarcz E, Hellman J, Wijkman M, et al.
Diabetologia
. 2024 Apr;
67(8):1517-1526.
PMID: 38668761
Aims/hypothesis: Previous studies have shown that individuals with similar mean glucose levels (MG) or percentage of time in range (TIR) may have different HbA values. The aim of this study...